Florian Krammer
Florian Krammer
確認したメール アドレス: mssm.edu
Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
A Grifoni, D Weiskopf, SI Ramirez, J Mateus, JM Dan, CR Moderbacher, ...
Cell 181 (7), 1489-1501. e15, 2020
A serological assay to detect SARS-CoV-2 seroconversion in humans
F Amanat, D Stadlbauer, S Strohmeier, THO Nguyen, V Chromikova, ...
Nature medicine 26 (7), 1033-1036, 2020
SARS-CoV-2 vaccines: status report
F Amanat, F Krammer
Immunity 52 (4), 583-589, 2020
Advances in the development of influenza virus vaccines
F Krammer, P Palese
Nature reviews Drug discovery 14 (3), 167-182, 2015
Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity
SV Bardina, P Bunduc, S Tripathi, J Duehr, JJ Frere, JA Brown, ...
Science 356 (6334), 175-180, 2017
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies
F Krammer, N Pica, R Hai, I Margine, P Palese
Journal of virology 87 (12), 6542-6550, 2013
Influenza virus hemagglutinin stalk-based antibodies and vaccines
F Krammer, P Palese
Current opinion in virology 3 (5), 521-530, 2013
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen, M Ogishi, ...
Science 370 (6515), 2020
SARS-CoV-2 vaccines in development
F Krammer
Nature 586 (7830), 516-527, 2020
Immune history profoundly affects broadly protective B cell responses to influenza
SF Andrews, Y Huang, K Kaur, LI Popova, IY Ho, NT Pauli, CJH Dunand, ...
Science translational medicine 7 (316), 316ra192-316ra192, 2015
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses
N Pica, R Hai, F Krammer, TT Wang, J Maamary, D Eggink, GS Tan, ...
Proceedings of the National Academy of Sciences 109 (7), 2573-2578, 2012
SARS‐CoV‐2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup
D Stadlbauer, F Amanat, V Chromikova, K Jiang, S Strohmeier, ...
Current protocols in microbiology 57 (1), e100, 2020
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes
R Hai, F Krammer, GS Tan, N Pica, D Eggink, J Maamary, I Margine, ...
Journal of virology 86 (10), 5774-5781, 2012
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
M Imai, K Iwatsuki-Horimoto, M Hatta, S Loeber, PJ Halfmann, ...
Proceedings of the National Academy of Sciences 117 (28), 16587-16595, 2020
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
J Lee, DR Boutz, V Chromikova, MG Joyce, C Vollmers, K Leung, ...
Nature medicine 22 (12), 1456-1464, 2016
Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection
CJH Dunand, PE Leon, M Huang, A Choi, V Chromikova, IY Ho, GS Tan, ...
Cell host & microbe 19 (6), 800-813, 2016
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses
I Margine, F Krammer, R Hai, NS Heaton, GS Tan, SA Andrews, ...
Journal of virology 87 (19), 10435-10446, 2013
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
STH Liu, HM Lin, I Baine, A Wajnberg, JP Gumprecht, F Rahman, ...
Nature medicine 26 (11), 1708-1713, 2020
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans
AH Ellebedy, F Krammer, GM Li, MS Miller, C Chiu, J Wrammert, ...
Proceedings of the National Academy of Sciences 111 (36), 13133-13138, 2014
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
A Wajnberg, F Amanat, A Firpo, DR Altman, MJ Bailey, M Mansour, ...
Science 370 (6521), 1227-1230, 2020
論文 1–20